drugset / Trial / NCT07458113
Sac-TMT for Active TNBC Brain Metastases
Phase 2
Not yet recruiting
20 enrolled
Yale University
Johns Hopkins University · collabMerck Sharp & Dohme LLC · collabTranslational Breast Cancer Research Consortium · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.
Timeline
- Start
- 2026-05
- Primary completion
- 2028-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |